{"id":1015301,"date":"2026-10-29T13:02:21","date_gmt":"2026-10-29T17:02:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/"},"modified":"2026-10-29T13:02:21","modified_gmt":"2026-10-29T17:02:21","slug":"elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/","title":{"rendered":"Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-bottom:7pt\">Keynote\/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer<\/li>\n<li style=\"margin-bottom:7pt\">Additional preclinical poster presentation showcases an expanded application of the AMP-platform in an antigen-agnostic intratumoral treatment approach<\/li>\n<\/ul>\n<p>BOSTON, Oct.  29, 2026  (GLOBE NEWSWIRE) &#8212; Elicio Therapeutics, Inc. (Nasdaq: ELTX) (\u201cElicio\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company will conduct a keynote\/plenary presentation, as well as two poster presentations showcasing additional results from the randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P) and an expanded antigen-agnostic intratumoral application of the AMP-adjuvant platform at the Society for Immunotherapy of Cancer\u2019s (\u201cSITC\u201d) Annual Meeting. The meeting will take place November 4-8, 2026 in Phoenix, Arizona.<\/p>\n<p>\n        <strong>Presentation Details: <\/strong>\n      <\/p>\n<p>\n        <strong>Keynote\/Plenary<\/strong><br \/>\n        <strong>Session<\/strong>\n      <\/p>\n<p>\n        <strong>Title: <\/strong>Updates on Clinical Results from the AMPLIFY-7P Study of a Lymph Node-Targeted KRAS Vaccine<br \/><strong>Presenter: <\/strong>Darrell J. Irvine, PhD, The Scripps Research Institute <br \/><strong>Session Number\/Name: <\/strong>103: Thomas Waldmann Memorial Plenary Session: Cancer Vaccines, Current and Future <br \/><strong>Presentation Date\/Time: <\/strong>Friday, November 6, 2026, at 10:04 am MT<br \/><strong>Location: <\/strong>Phoenix Convention Center \u2013 North Building \u2013 300 Level \u2013 Halls BC<\/p>\n<p>\n        <strong>Late-Breaking Abstract Poster Presentation <\/strong>\n      <\/p>\n<p>\n        <strong>Title: <\/strong>Seven valent mKRAS lymph node targeted amphiphile vaccine drives mKRAS-specific T cell responses that correlate with improved clinical outcomes in the AMPLIFY-7P randomized phase 2 trial <br \/><strong>Presenter: <\/strong>Christopher M. Haqq<br \/><strong>Abstract Number: <\/strong>1186<br \/><strong>Session Date\/Time: <\/strong>Saturday, November 7, 2026, 12:30-1:30 pm MT and 6:40-8:10 pm MT<br \/><strong>Location: <\/strong>Phoenix Convention Center \u2013 North Building -Lower Level \u2013 Exhibition Halls 4-6<\/p>\n<p>\n        <strong>Poster Presentation <\/strong>\n      <\/p>\n<p>\n        <strong>Title: <\/strong>Direct intratumoral delivery of amphiphilic immunomodulators induces durable anti-tumor efficacy <br \/><strong>Presenter: <\/strong>Martin Steinbuck<br \/><strong>Abstract Number: <\/strong>824<br \/><strong>Session Date\/Time: <\/strong>Saturday, November 7, 2026, at 12:30-1:30pm MT and 6:40-8:10pm MT<br \/><strong>Location: <\/strong>Phoenix Convention Center \u2013 North Building \u2013 Lower Level &#8211; Exhibition Halls 4-6<\/p>\n<p>\n        <strong>About the AMPLIFY-7P Phase 2 Study<\/strong>\n      <\/p>\n<p>AMPLIFY-7P Phase 2 is a randomized study evaluating camupepimut (ELI-002 7P) versus observation in patients with mutant KRAS-driven pancreatic ductal adenocarcinoma following completion of standard locoregional therapy. The study enrolled 144 patients across 24 U.S. clinical sites.<\/p>\n<p>\n        <strong> About camupepimut (ELI-002 7P) <\/strong>\n      <\/p>\n<p>Camupepimut is an investigational, off-the-shelf immunotherapy designed to generate immune responses against seven of the most common KRAS mutations. Camupepimut utilizes Elicio\u2019s proprietary Amphiphile (\u201cAMP\u201d) technology to target mutant KRAS peptide antigens and an immune-stimulatory adjuvant directly to the lymph nodes, where adaptive immune responses are orchestrated.<\/p>\n<p>\n        <strong>About Elicio Therapeutics <\/strong>\n      <\/p>\n<p>Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing next-generation immunotherapies for the treatment of KRAS-driven cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical findings in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies.<\/p>\n<p>Elicio\u2019s AMP technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio\u2019s camupepimut lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors.<\/p>\n<p>Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid, commercial-scale manufacturing and rapid availability of drug to patients, especially in neoadjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches.<\/p>\n<p>Elicio\u2019s pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, which target BRAF-driven cancers and p53 hotspot mutations, respectively.<\/p>\n<p>For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IVnLdbQ0w201rblr-TtgCz1qCMa2zOOOWAjE7Yg-4KSOAtj24Tu__giXhvtxwPQuFYHW8rhZfAkxJRqB-n0GQw==\" rel=\"nofollow\" target=\"_blank\">www.elicio.com<\/a>.<\/p>\n<p>\n        <strong>Cautionary Note on Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Certain statements contained in this communication regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA.<\/p>\n<p>These include statements regarding the timing and content of Elicio\u2019s presentation at SITC 2026 Annual Meeting; the clinical activity, therapeutic potential and potential benefits of camupepimut (ELI-002 7P); the interpretation and potential implications of results and analyses from Elicio\u2019s preclinical studies; the interpretation and potential implications of results and analyses from Elicio\u2019s AMPLIFY-7P study, including the observation that mKRAS-specific T cell responses correlate with improved clinical outcomes; Elicio\u2019s planned clinical programs, including planned clinical trials; the potential of Elicio\u2019s product candidates and platform; the potential for pre-specified analyses to further characterize the clinical activity of camupepimut (ELI-002 7P); the potential benefits and effectiveness of off-the-shelf immunotherapy approaches; the potential participation and presentation at upcoming conferences and medical meetings; and other statements regarding management\u2019s intentions, plans, beliefs, expectations or forecasts for the future and, therefore, you are cautioned not to place undue reliance on them.<\/p>\n<p>No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Elicio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law.<\/p>\n<p>Elicio uses words such as \u201canticipates,\u201d \u201cbelieves,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201cprojects,\u201d \u201cfuture,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cguidance,\u201d and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA.<\/p>\n<p>Such forward-looking statements are based on Elicio\u2019s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, Elicio\u2019s plans to develop and commercialize its product candidates, including camupepimut; the timing of initiation of Elicio\u2019s planned clinical trials; the timing of the availability and presentation of data from Elicio\u2019s clinical trials; the design and timing of future clinical trials; the timing of any planned investigational new drug application or new drug application; Elicio\u2019s plans to research, develop and commercialize its current and future product candidates; and Elicio\u2019s estimates regarding future revenue, expenses, capital requirements and need for additional financing. New factors emerge from time to time, and it is not possible for Elicio to predict all such factors, nor can Elicio assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.<\/p>\n<p>These risks are more fully discussed under the heading \u201cRisk Factors\u201d in Elicio\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the \u201cSEC\u201d) on March 12, 2026, as amended on April 29, 2026, Elicio\u2019s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 11, 2026, and Elicio\u2019s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 13, 2026, as updated by subsequent reports and other documents filed from time to time with the SEC.<\/p>\n<p>Forward-looking statements included in this release are based on information available to Elicio as of the date of this release. Elicio does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this release, except to the extent required by law.<\/p>\n<p>\n        <strong>Elicio Investor Relations Contact<\/strong>\n      <\/p>\n<p>Brian Ritchie<br \/>LifeSci Advisors<br \/>(212) 915-2578<br \/>britchie@lifesciadvisors.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTgzNiM3OTEwMTM2IzIyMDg2Nzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTdmYmFjYTItODhiMC00NDY4LTkwZTYtODM0ZDg5ZjJkNjM5LTEyMjAyMzItMjAyNi0xMC0yOS1lbg==\/tiny\/Elicio-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Keynote\/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer Additional preclinical poster presentation showcases an expanded application of the AMP-platform in an antigen-agnostic intratumoral treatment approach BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) &#8212; Elicio Therapeutics, Inc. (Nasdaq: ELTX) (\u201cElicio\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company will conduct a keynote\/plenary presentation, as well as two poster presentations showcasing additional results from the randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P) and an expanded antigen-agnostic intratumoral application of the AMP-adjuvant platform at the Society for Immunotherapy of Cancer\u2019s (\u201cSITC\u201d) Annual Meeting. The meeting will take place &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1015301","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Keynote\/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer Additional preclinical poster presentation showcases an expanded application of the AMP-platform in an antigen-agnostic intratumoral treatment approach BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) &#8212; Elicio Therapeutics, Inc. (Nasdaq: ELTX) (\u201cElicio\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company will conduct a keynote\/plenary presentation, as well as two poster presentations showcasing additional results from the randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P) and an expanded antigen-agnostic intratumoral application of the AMP-adjuvant platform at the Society for Immunotherapy of Cancer\u2019s (\u201cSITC\u201d) Annual Meeting. The meeting will take place &hellip; Continue reading &quot;Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-29T17:02:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTgzNiM3OTEwMTM2IzIyMDg2Nzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting\",\"datePublished\":\"2026-10-29T17:02:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\\\/\"},\"wordCount\":1179,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTgzNiM3OTEwMTM2IzIyMDg2Nzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\\\/\",\"name\":\"Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTgzNiM3OTEwMTM2IzIyMDg2Nzk=\",\"datePublished\":\"2026-10-29T17:02:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTgzNiM3OTEwMTM2IzIyMDg2Nzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTgzNiM3OTEwMTM2IzIyMDg2Nzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting - Market Newsdesk","og_description":"Keynote\/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer Additional preclinical poster presentation showcases an expanded application of the AMP-platform in an antigen-agnostic intratumoral treatment approach BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) &#8212; Elicio Therapeutics, Inc. (Nasdaq: ELTX) (\u201cElicio\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company will conduct a keynote\/plenary presentation, as well as two poster presentations showcasing additional results from the randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P) and an expanded antigen-agnostic intratumoral application of the AMP-adjuvant platform at the Society for Immunotherapy of Cancer\u2019s (\u201cSITC\u201d) Annual Meeting. The meeting will take place &hellip; Continue reading \"Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-29T17:02:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTgzNiM3OTEwMTM2IzIyMDg2Nzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting","datePublished":"2026-10-29T17:02:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/"},"wordCount":1179,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTgzNiM3OTEwMTM2IzIyMDg2Nzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/","name":"Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTgzNiM3OTEwMTM2IzIyMDg2Nzk=","datePublished":"2026-10-29T17:02:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTgzNiM3OTEwMTM2IzIyMDg2Nzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTgzNiM3OTEwMTM2IzIyMDg2Nzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1015301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1015301"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1015301\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1015301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1015301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1015301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}